University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
NCT Number: NCT01346072
This pilot study will investigate the association between levels of the peptide copeptin and response to tolvaptan, a drug that blocks the action of the water retaining hormone vasopressin. The study will enroll stable outpatients with CHF with reduced LVEF (≤45) selected by targeting upper and lower quartile copeptin levels at screening (10 each). The treatment phase of the study will be a prospective, single-arm, open label protocol. All patients will receive active therapy consisting of a single oral dose of 30 mg of tolvaptan with body weight, fluid intake, and urine output monitored in a research unit for 24 hours.
For analysis of study endpoints, patients in the single intervention arm will be stratified by a prospectively determined cut-point of copeptin level into two groups (≥10 versus <10 pmol/L). The copeptin level used for the two group stratification will be the blinded copeptin value obtained at baseline from the hospital phase prior to administration of tolvaptan.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Chapel Hill, North Carolina, 27514, United States
The study screening strategy will be designed to enroll an enriched patient population by identifying patients at the high or low end of the spectrum of copeptin levels for outpatients with stable heart failure. This will be accomplished by blinded review of copeptin levels obtained during screening.
The primary endpoints for analysis will be 24 hour urine output and the change in body weight over 24 hours during the inpatient stay.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
j. Subjects judged by the investigator to be unable to maintain accurate intake and output during their hospitalization related to medical or other problems
oral, 30 mg, single dose, one time administration
Other names: Samsca
Time frame: 24 hours
Total urine output for 24 hours following tolvaptan administration
Time frame: Change over 24 hours
Change in body weight from baseline to 24 hours after tolvaptan administration
University of North Carolina, Chapel Hill
Other
Pilot Study of the Relationship of Ambient Copeptin to the Aquaretic Effects of Tolvaptan in Patients With Heart Failure
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06215911
Cardiovascular Diseases, Heart Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06215586
Cardiovascular Diseases, Heart Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT04444583
Cardiovascular Diseases, Heart Diseases
Helsinki, Finland
View Trial DetailsNCT04634708
Cardiomyopathies, Cardiovascular Diseases
Berlin, Germany
View Trial Details